We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

81 hedge funds and large institutions have $273M invested in Adamas Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 24

12% more capital invested

Capital invested by funds: $243M → $273M (+$29.5M)

4% less funds holding

Funds holding: 84 → 81 (-3)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

50% less funds holding in top 10

Funds holding in top 10: 6 → 3 (-3)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $358K

Holders
81
Holders Change
-3
Holders Change %
-3.57%
% of All Funds
2.16%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.08%
New
7
Increased
27
Reduced
24
Closed
10
Calls
–
Puts
$358K
Net Calls
-$358K
Net Calls Change
-$26K

Top Buyers

Rank Fund Capital Flow
1
BS
Bow Street
New York
+$10.1M
2
GPP
Great Point Partners
Connecticut
+$7.48M
3
Millennium Management
Millennium Management
New York
+$2.44M
4
BWCA
Brenner West Capital Advisors
New York
+$2.31M
5
NC
Nexthera Capital
New York
+$1.53M

Top Sellers

Rank Fund Capital Flow
1
CPH
C Partners Holding
Switzerland
-$8.78M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.47M
3
IHM
Iguana Healthcare Management
New York
-$1.51M
4
SM
Sabby Management
Florida
-$1.05M
5
TC
TFS Capital
Pennsylvania
-$943K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
76
Bank of America
North Carolina
$14K -$21.8K -1,435 -63%
Citigroup
77
Citigroup
New York
$5K -$49.5K -3,256 -92%
Barclays
78
Barclays
United Kingdom
$3K -$912 -60 -22%
CSS
79
Cubist Systematic Strategies
Connecticut
$2K -$16.4K -1,081 -88%
MFS
80
MSI Financial Services
Massachusetts
$2K – – –
TCIM
81
TIAA CREF Investment Management
New York
$887 -$11.6K -760 -1%
IHM
82
Iguana Healthcare Management
New York
– -$1.51M -100,000 Closed
TC
83
TFS Capital
Pennsylvania
– -$943K -62,318 Closed
ZIM
84
Zacks Investment Management
Illinois
– -$685K -45,273 Closed
TI
85
Trexquant Investment
Connecticut
– -$554K -36,617 Closed
Balyasny Asset Management
86
Balyasny Asset Management
Illinois
– -$305K -20,152 Closed
UBS AM
87
UBS AM
Illinois
– -$259K -17,110 Closed
PAM
88
Panagora Asset Management
Massachusetts
– -$22K -1,459 Closed
TRCT
89
Tower Research Capital (TRC)
New York
– -$2K -100 Closed
PMFA
90
Plante Moran Financial Advisors
Michigan
– -$1K -47 Closed
1 2 3
4

ADMS Hedge Fund Activity: Q3 2016 in Review

81 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2016, worth a combined $273M — up 12% from $243M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ADMS and 7 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 27 added.

The largest buyer was Bow Street, adding an estimated $10.1M. The largest seller was C Partners Holding, cutting an estimated $8.78M.

  • 81 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2016, down from 84 in Q2 2016.
  • Funds reported $273M of Adamas Pharmaceuticals stock for Q3 2016, up 12% quarter-over-quarter.
  • 7 funds opened new Adamas Pharmaceuticals positions in Q3 2016 and 10 closed out, a net change of -3 holders.
  • The largest Adamas Pharmaceuticals buyer in Q3 2016 was Bow Street, an estimated $10.1M added.
  • The largest Adamas Pharmaceuticals seller in Q3 2016 was C Partners Holding, an estimated $8.78M sold.

Based on aggregated 13F filings for Q3 2016.